Table 2.

Intracranial tumor response by IRC assessment in patients with RET fusion-positive NSCLC and measurable intracranial disease per RECIST 1.1.

Patients with measurable intracranial disease (N = 22)
Intracranial ORR, n (%)18 (82)
 95% confidence intervala60–95
Intracranial best overall response, n (%)
 CR5 (23)
 PR13 (59)
 SD4 (18)
 PD0
Intracranial disease control rate, n (%)b22 (100)
  • a95% CI was calculated using Clopper–Pearson method.

  • bIntracranial disease control rate was defined as the percentage of patients who had a best overall intracranial response of CR, PR, or SD lasting 16 weeks or more after selpercatinib initiation.